Clinical trials: Severe Respiratory Distress
ARDS, Acute Lung Injury
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO
The acute respiratory distress syndrome (ARDS) is the most severe form of respiratory failure, presented in 10% of all intensive care patients and carrying a high mortality rate.
- Conditions
- ARDS, Acute Lung Injury, Extracorporeal Membrane Oxygenation, Respiratory Distress Syndrome
- Trial name
- NCT03764319
- Testing
- Ultra-protective ventilator settings, Standard ventilator settings
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- Medical University of Vienna
Infant, Premature, Diseases, Respiratory Distress Syndrome, Newborn
Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia
Advances in perinatal care have made it possible to improve the survival of the most immature neonates, but at the cost of an increase in the population at risk of developing bronchopulmonary dysplasia (BPD).
- Conditions
- Infant, Premature, Diseases, Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia
- Trial name
- CURDYS (NCT01039285)
- Testing
- Curosurf, Air
- Where
- 13 sites in France
- Volunteers
- 118 people
- Sponsor
- Jean Michel Hascoet
Respiratory Distress Syndrome, Adult
ARDSnet Protocol vs. Open Lung Approach in ARDS
Many patients with Acute Respiratory Distress Syndrome or ARDS need breathing support that is provided by a machine called a ventilator or respirator.
- Trial name
- NCT00431158
- Testing
- Different Mechanical Ventilation Protocols
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Massachusetts General Hospital
Human Anaplasmosis
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace.
- Trial name
- ANARETRO (NCT07312474)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Severe Acute Respiratory Distress Syndrome / Severe ARDS, Invasive Mechanical Ventilation
Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients
The acute respiratory distress syndrome (ARDS) is common condition in critical ill patients affecting 7.2 people / 100,000 population / year and more than 7% of patients with invasive mechanical ventilation for more than 24…
- Conditions
- Severe Acute Respiratory Distress Syndrome / Severe ARDS, Invasive Mechanical Ventilation, Individualized PEEP Treatment Strategy
- Trial name
- ENCODE (NCT02617914)
- Testing
- individualized PEEP treatment, Invasive mechanical ventilation, ECMO,
- Sponsor
- RWTH Aachen University
Coronavirus Infection, COVID
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
Prone positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ARDS) patients, with demonstrated reductions in mortality.
- Conditions
- Coronavirus Infection, COVID, Severe Acute Respiratory Syndrome, Respiratory Failure
- Trial name
- COVAYDE (NCT04395144)
- Testing
- Awake Prone Positioning, Standard care
- Where
- 5 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Hôpital de Verdun
COVID-19, Acute Respiratory Distress Syndrome
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- SINK COVID-19 (NCT04365985)
- Testing
- Naltrexone, Ketamine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Corewell Health East
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Distress Syndrome, Hypercapnia
Correction by ECCO2-R of Hypercapnia in Patients With DVP in Moderate to Severe ARDS Under Protective Ventilation.
Pulmonary vascular dysfunction (DVP) is associated with a pejorative prognosis during ARDS. There is no specific therapeutic intervention to thwart it.
- Trial name
- COVAP (NCT03303807)
- Testing
- Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dyspnea
Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER (NCT04569266)
- Testing
- Specific exercise rehabilitation treatment, No specific exercise rehabilitation treatment
- Where
- 3 sites in France
- Volunteers
- 63 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Acute Severe Respiratory Failure, Acute Respiratory Distress Syndrome
Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE
We wish to prospectively assess the burden of, management and therapeutic approaches to, and outcomes from acute hypoxaemic respiratory failure requiring ventilatory support, during the winter months in both the northern and…
- Trial name
- LUNG-SAFE (NCT02010073)
- Where
- Belgium
- Volunteers
- 14,000 people
- Sponsor
- European Society of Intensive Care Medicine
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
Covid-19
Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres
- Trial name
- ECMO-SL-CoV-2 (NCT04446286)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
COVID
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
This is a phase 1b randomized, double-blind, placebo-controlled study in adult subjects with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04397796
- Testing
- BM-Allo.MSC
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure.
- Conditions
- SARS (Severe Acute Respiratory Syndrome), Cytokine Storm, ARDS, Human, COVID-19
- Trial name
- COVID-19-HBO (NCT04327505)
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 34 people
- Sponsor
- Karolinska Institutet
Acute Respiratory Distress Syndrome, Ventilator Lung
FCV vs PCV in Moderate to Severe ARDS
The goal of this clinical trial is to compare flow-controlled ventilation (FCV) and pressure-controlled ventilation (PCV) in patients with moderate to severe acute respiratory distress syndrome on the intensive care unit.
- Trial name
- NCT06051188
- Testing
- Flow-controlled ventilation
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Erasmus Medical Center
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04973488
- Testing
- Therapeutic plasma exchange
- Where
- Romania
- Volunteers
- 38 people
- Sponsor
- Novacescu Alexandru
Acute Respiratory Distress Syndrome
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the…
- Trial name
- ARDS (NCT07413978)
- Testing
- 1 vial containing a total of 5×10^7 cells, 2 vial containing a total of 1×10^8 cells, 3 vial containing a total of 1.5×10^8 cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changchun Tuohua Pharmaceutical Co., Ltd.
COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis)
Psilocybin Therapy for Psychological Distress in Palliative Patients
The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
- Trial name
- PsyPal (NCT06782724)
- Testing
- Psilocybin therapy
- Where
- 4 sites in Czechia, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- University Medical Center Groningen